QCG
AKBA icon

Quadrant Capital Group’s Akebia Therapeutics AKBA Stock Holding History

Quadrant Capital Group’s Portfolio AKBA Stock Details AKBA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-947
Closed -$4K – 2484
2021
Q2 		$4K Buy
+947
New +$3.19K ﹤0.01% 1890
2020
Q3 		– Sell
-3,315
Closed -$45K – 2151
2020
Q2 		$45K Buy
+3,315
New +$34.3K 0.01% 760
2018
Q3 		– Sell
-3,315
Closed -$33K – 2126
2018
Q2 		$33K Hold
3,315
– – 0.01% 790
2018
Q1 		$31K Buy
+3,315
New +$46.4K 0.01% 788

Other funds holding AKBA

State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
AIM
Alerce Investment Management Chicago, Illinois $56.8M AUM 31.17% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

Quadrant Capital Group's AKBA Position: Q3 2021 in Review

Quadrant Capital Group sold out of Akebia Therapeutics (AKBA) in Q3 2021, closing a stake of 947 shares — an estimated $4K sold.

Quadrant Capital Group first reported a position in AKBA in Q1 2018 and held it in 4 quarters. The position peaked at $45K in Q2 2020. 126 funds tracked by Wall St. Rank hold AKBA as of Q3 2021.

  • Quadrant Capital Group reported no remaining Akebia Therapeutics position as of Q3 2021 after selling out during the quarter.
  • Quadrant Capital Group sold 947 Akebia Therapeutics shares in Q3 2021, an estimated $4K.
  • Quadrant Capital Group first reported a position in Akebia Therapeutics in Q1 2018 and held it in 4 quarters.
  • Quadrant Capital Group's Akebia Therapeutics position peaked at $45K in Q2 2020.
  • 126 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q3 2021.

Based on Quadrant Capital Group's 13F filing for Q3 2021, filed 12 Nov 2021.